Harnessing Vδ1+ T cells for next-generation immunotherapy: from mechanistic insights to clinical translation

1

Vδ1+ T cells can recognize targets in an MHC-unrestricted manner, making them promising candidates for cancer immunotherapy.
2

These cells exhibit the ability to penetrate solid tumors and demonstrate functional plasticity in inflammatory tumor microenvironments.
3

Vδ1+ T cells show distinct advantages over conventional αβ T cells, including lower risk of graft-versus-host disease and reduced cytokine release syndrome.
4

The review highlights the challenges in clinical translation of Vδ1+ T cell therapies, including product standardization and microenvironmental suppression.
5

Understanding the biological characteristics of Vδ1+ T cells is crucial for developing effective immunotherapies against solid tumors.

1